Cabaletta Bio
@cabalettabio
Transforming the treatment of B cell-mediated autoimmune diseases
ID: 1060899048566259712
http://www.cabalettabio.com 09-11-2018 14:16:58
58 Tweet
475 Takipçi
152 Takip Edilen
Cabaletta Bio announces publication in the JCI of preclinical results for DSG3-CAART in #pemphigus vulgaris (PV), which supported the opening of the DesCAARTes Phase 1 clinical trial in patients with mucosal-dominant PV investors.cabalettabio.com/news-releases/…
The DesCAARTes™ Phase 1 clinical trial is now recruiting patients with mucosal-dominant pemphigus vulgaris, and we are thankful to the healourskin for letting us share our passion to discover and develop cures for patients with #autoimmune diseases pemphigus.org/wp-content/upl…
Philadelphia’s cell and gene therapy industry is at a tipping point and Cabaletta Bio is excited to be part of the movement bizjournals.com/philadelphia/n…
Cabaletta Bio announces 1st patient dosed in landmark DesCAARTes™ trial of DSG3-CAART for treatment of patients with mucosal-dominant pemphigus vulgaris #CAART #autoimmune #CellTherapy investors.cabalettabio.com/news-releases/…
The 1st patient in the DesCAARTes™ Phase 1 clinical trial has been dosed, and the trial is recruiting patients with mucosal-dominant pemphigus vulgaris. We are thankful to healourskin for giving us the opportunity to communicate our progress pemphigus.org/wp-content/upl…